Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. (-)-platensimycin
2. 835876-32-9
3. Q3dq78kofy
4. Chebi:68236
5. 3-[3-[(1s,5s,6r,7s,9s,10s)-5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.17,10.01,6]tridec-2-en-5-yl]propanoylamino]-2,4-dihydroxybenzoic Acid
6. Pmn
7. 3-({3-[(1s,4as,6s,7s,9s,9ar)-1,6-dimethyl-2-oxo-1,2,5,6,7,8,9,9a-octahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic Acid
8. Benzoic Acid, 3-((3-((1s,3s,4s,5as,9s,9ar)-1,4,5,8,9,9a-hexahydro-3,9-dimethyl-8-oxo-3h-1,4:3,5a-dimethano-2-benzoxepin-9-yl)-1-oxopropyl)amino)-2,4-dihydroxy-
9. Unii-q3dq78kofy
10. Platensimycin [mi]
11. Platensimycin, (-)-
12. Chembl411278
13. Dtxsid80894888
14. Zinc29050726
15. Db08407
16. Ncgc00183212-01
17. Hy-127146
18. Cs-0093585
19. C20132
20. Q423275
21. 3-((3-((1s,3s,4s,5as,9s,9ar)-1,4,5,8,9,9a-hexahydro-3,9-dimethyl-8-oxo-3h-1,4:3,5a-dimethano-2-benzoxepin-9-yl)-1-oxopropyl)amino)-2,4-dihydroxybenzoic Acid
| Molecular Weight | 441.5 g/mol |
|---|---|
| Molecular Formula | C24H27NO7 |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | 441.17875220 g/mol |
| Monoisotopic Mass | 441.17875220 g/mol |
| Topological Polar Surface Area | 133 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 888 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Infective Agents
Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)
Fatty Acid Synthesis Inhibitors
Compounds that interfere with FATTY ACID SYNTHASE resulting in a reduction of FATTY ACIDS. This is a target mechanism in humans of some ANTINEOPLASTIC AGENTS and ANTI-OBESITY AGENTS and of some ANTI-INFECTIVE AGENTS which interfere with CELL WALL and CELL MEMBRANE formation. (See all compounds classified as Fatty Acid Synthesis Inhibitors.)
ABOUT THIS PAGE
55
PharmaCompass offers a list of Platensimycin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Platensimycin manufacturer or Platensimycin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Platensimycin manufacturer or Platensimycin supplier.
PharmaCompass also assists you with knowing the Platensimycin API Price utilized in the formulation of products. Platensimycin API Price is not always fixed or binding as the Platensimycin Price is obtained through a variety of data sources. The Platensimycin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Platensimycin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Platensimycin, including repackagers and relabelers. The FDA regulates Platensimycin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Platensimycin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Platensimycin supplier is an individual or a company that provides Platensimycin active pharmaceutical ingredient (API) or Platensimycin finished formulations upon request. The Platensimycin suppliers may include Platensimycin API manufacturers, exporters, distributors and traders.
Platensimycin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Platensimycin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Platensimycin GMP manufacturer or Platensimycin GMP API supplier for your needs.
A Platensimycin CoA (Certificate of Analysis) is a formal document that attests to Platensimycin's compliance with Platensimycin specifications and serves as a tool for batch-level quality control.
Platensimycin CoA mostly includes findings from lab analyses of a specific batch. For each Platensimycin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Platensimycin may be tested according to a variety of international standards, such as European Pharmacopoeia (Platensimycin EP), Platensimycin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Platensimycin USP).
